BioStorage Launches INTEGRITY Study
News Aug 22, 2013
BioStorage Technologies has announced that the company has initiated the INTEGRITY Study. The 24-month study will analyze human whole blood samples to measure the impact on the long-term integrity of DNA and RNA when various preparation methods, storage temperatures and storage times are applied.
Conducted at BioStorage Technologies’ global biorepository in Indianapolis, the study will compare fresh samples, frozen pre-extracted samples and extracted nucleic acids, which require freeze/ thaw cycles for processing.
Various storage temperatures and aliquoting strategies will be evaluated and reported over the length of the study.
“The INTEGRITY study has a unique comprehensive study design that will help provide the industry with recommended best practices and techniques to support the optimal preservation of DNA and RNA samples for prospective and retrospective research studies,” said Lori Ball, COO, BioStorage Technologies.
Ball continued, “Our goal is to determine the effects of various preparation methods on whole blood samples for nucleic acid extraction and the optimal length of time and best temperature to store samples for future research.”
Existing research suggests that inexact sample preparation and storage methods may affect the results or analysis of biological studies and can lead to sample loss, reprocessing or complicated data interpretation.
However, to date, most studies have been designed to analyze the impact of a single temperature and have not been focused on the long-term effects of various temperatures, methods of freeze-thaw and storage time on DNA and RNA integrity within a single study.
“As an advocate for advancing the global biobanking industry, BioStorage Technologies has become an informational resource for best practices at all stages of the sample management life-cycle, and with the INTEGRITY Study we hope to provide data-driven research in a comprehensive single-study format that has never before been done,” said Greg Swanberg, CEO, Biostorage Technologies.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE